nitric oxide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-20 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Langlykke who visited the Argentine lab once a year. In 1960, he offered Ondetti a job to work in the New Jersey laboratory. Within two days, Ondetti decided to take the job in New Jersey for $7800 a year.
=== Synthesis === The first reported manufacturing process for pregabalin was reported by Hoekstra and colleagues at Warner-Lambert in 1997, developed under the investigational name CI-1008. Initial preparations used an Evans chiral auxiliary to establish the (S)-stereocentre, but the selected manufacturing route employed racemic synthesis of 3-(aminomethyl)-5-methylhexanoic acid followed by diastereomeric salt formation with (S)-(+)-mandelic acid as the resolving agent. A more efficient enantioselective route was subsequently reported by Burk and colleagues, in which asymmetric hydrogenation of a salt of 3-cyano-5-methylhex-3-enoic acid using a rhodium/(R,R)-Me-DuPHOS catalyst gives the (S)-cyano intermediate in high enantiomeric excess (≥95% ee), followed by heterogeneous nickel-catalysed hydrogenation of the nitrile to afford pregabalin. A second-generation chemoenzymatic manufacturing process reported by Pfizer in 2008 uses a lipase-catalysed kinetic resolution of 2-carboxyethyl-3-cyano-5-methylhexanoic acid ethyl ester (CNDE) with Lipolase (a Thermomyces lanuginosus lipase supplied commercially by Novozymes), followed by thermal decarboxylation and nitrile reduction to give the final product. Following patent expiry, generic manufacturing routes have also been developed, including a process reported by Dr. Reddy's Laboratories in 2021 that combines continuous-flow nitroalkene synthesis with an asymmetric organocatalytic Michael addition as the stereodetermining step.
In October 2020, Gilead and HHS announced that HHS was relinquishing control over remdesivir allocation because production of the drug had finally caught up with US domestic demand. AmerisourceBergen will remain the sole distributor of Veklury in the US through the end of 2020. On 22 October 2020, the FDA approved remdesivir and also revised the EUA to permit the use of remdesivir for treatment of suspected or laboratory confirmed COVID‑19 in hospitalized children weighing 3.5 kilograms (7.7 lb) to less than 40 kilograms (88 lb) or hospitalized children less than twelve years of age weighing at least 3.5 kilograms (7.7 lb). This decision was criticized for an alleged lack of previous consultation on part of the FDA given the complications of antiviral drug issues. In November 2020, the FDA issued an EUA for the combination of baricitinib with remdesivir, for the treatment of suspected or laboratory-confirmed COVID‑19 in hospitalized people two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The data supporting the EUA for baricitinib combined with remdesivir are based on a randomized, double-blind, placebo-controlled clinical trial (ACTT-2), which was conducted by the National Institute of Allergy and Infectious Diseases (NIAID). The EUA was issued to Eli Lilly and Company. Remdesivir received approval from the US Food and Drug Administration (FDA) in October 2020, for use in adults and children twelve years and older requiring hospitalization for treatment of severe COVID‑19 infections.
Sources: en.wikipedia.org
=== Essendon === On 24 August 2026, McVeigh was appointed the senior coach of the Essendon Football Club on the three year contract, returning to the club where he played his entire playing career. McVeigh replaced caretaker senior coach Dean Solomon, who replaced senior coach Brad Scott after Scott was sacked in the middle of the 2026 AFL season.
== Strategies to limit drug prices in the United States == In the United States there are many resources available (to both state and local governments, and to patients directly) to lower the price patients must pay for medications; such costs can include copayments, coinsurance, and deductibles. The Medicaid Drug Rebate Program is one example. Generic drug programs lower the amount of money patients have to pay when picking up their prescription at the pharmacy. As their name implies, they only cover generic drugs. Co-pay assistance programs are programs that help patients lower the costs of specialty medications; i.e., medications that are on restricted formularies, have limited distribution, and/or have no generic version available. These medications can include drugs for HIV, hepatitis C, and multiple sclerosis. Patient Assistance Program Center (RxAssist) has a list of foundations that provide co-pay assistance programs. Co-pay assistance programs are for under-insured patients. Patients without insurance are not eligible for this resource; however, they may be eligible for patient assistance programs. Patient assistance programs are funded by the manufacturer of the medication. Patients can often apply to these programs through the manufacturer's website. This type of assistance program is one of the few options available to uninsured patients. The out-of-pocket cost for patients enrolled in co-pay assistance or patient assistance programs is $0.
Time of flight (ToF) is the measurement of the time taken by an object, particle or wave (be it acoustic, electromagnetic, etc.) to travel a distance through a medium. This information can then be used to measure velocity or path length, or as a way to learn about the particle or medium's properties (such as composition or flow rate). The traveling object may be detected directly (direct time of flight, dToF, e.g., via an ion detector in mass spectrometry) or indirectly (indirect time of flight, iToF, e.g., by light scattered from an object in laser doppler velocimetry). Time of flight technology has found valuable applications in the monitoring and characterization of material and biomaterials, hydrogels included.
Sources: en.wikipedia.org
Communicates with sensory neurons. Mesencephalon Also known as the midbrain, this region of the brainstem is involved in motor control, vision, hearing, and alertness. Metabotropic receptor A type of neurotransmitter receptor that activates a second messenger system via G-proteins, resulting in slower but longer-lasting cellular effects. Microelectrode A very fine electrode used to record the electrical activity of individual neurons. Microglia The resident immune cells of the central nervous system, responsible for clearing debris, responding to injury, and regulating inflammation. Middle ear The air-filled space containing the auditory ossicles (malleus, incus, stapes) that transmit sound from the outer ear to the inner ear. Midbrain A portion of the brainstem that includes structures such as the tectum and tegmentum. It plays roles in vision, hearing, motor control, and arousal. Mismatch negativity (MMN) An event-related potential detected via EEG that reflects automatic brain response to deviations in auditory stimuli. Used in studies of perception and schizophrenia. Mitochondria Organelles responsible for energy production in cells. In neurons, they play critical roles in metabolism, calcium regulation, and apoptosis. Molecular layer The outermost layer of the cerebellar cortex and cerebral cortex (in some regions), containing relatively few neurons and mostly dendrites, axons, and synapses. Monoamine oxidase (MAO) An enzyme that breaks down monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine. Targeted by some antidepressants.
=== He–Hi === Clayton Heathcock (born 1936), American chemist known for his work on the synthesis of complex polycyclic natural products Alan J. Heeger (1936–2023), American chemist known for co-founding the field of conducting polymers, 2000 Nobel Prize in chemistry Jan Baptist van Helmont (1579–1644), chemist from the Spanish Netherlands known for studying the weight gain of growing plants, The founder of pneumatic chemistry Victor Henri (1872–1940), French physical chemist of Russian parents, the first to apply ideas of physical chemistry to the properties of enzymes. Dudley R.
== Lecturer == From 2005 to 2013, he served as a neurophysiology researcher at the University of Ulm.[23] In 2014, he received a lifelong appointment as Visiting Professor at the Instituto Universitario de Ciencias de la Salud, Buenos Aires.[17] Since 2019, Schleip has been a Research Associate and, since 2024, a Senior Scientist at the professorship of conservative and rehabilitative orthopaedics in the TUM School of Medicine & Health at the Technical University of Munich.[23]
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.